Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Enrollment in dose escalation and backfill cohort
Read moreEnrollment in dose escalation and backfill cohort
Read moreFourth Quarter and Full Year 2023 Overview (all co
Read moreNEW YORK and SAN DIEGO, Feb.
Read moreSPRING, Texas, Feb.
Read moreJan De Witte to retire as CEO by the end of 2024St
Read moreThe Financial Services Innovation Coalition (FSIC
Read morePRINCETON, N.J., Feb.
Read moreFourth Quarter Highlights Contract revenues of $9
Read moreSCOTTSDALE, Ariz., Feb.
Read moreRecorded Investment Gains of Over $25 million and
Read more